GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PeptiDream Inc (OTCPK:PPTDF) » Definitions » EV-to-EBITDA

PPTDF (PeptiDream) EV-to-EBITDA : 9.37 (As of May. 28, 2025)


View and export this data going back to 2014. Start your Free Trial

What is PeptiDream EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PeptiDream's enterprise value is $1,392.8 Mil. PeptiDream's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $148.6 Mil. Therefore, PeptiDream's EV-to-EBITDA for today is 9.37.

The historical rank and industry rank for PeptiDream's EV-to-EBITDA or its related term are showing as below:

PPTDF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8   Med: 118.44   Max: 2798.49
Current: 8.52

During the past 13 years, the highest EV-to-EBITDA of PeptiDream was 2798.49. The lowest was 8.00. And the median was 118.44.

PPTDF's EV-to-EBITDA is ranked worse than
52.5% of 501 companies
in the Biotechnology industry
Industry Median: 8.16 vs PPTDF: 8.52

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-28), PeptiDream's stock price is $13.53. PeptiDream's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $0.716. Therefore, PeptiDream's PE Ratio (TTM) for today is 18.90.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


PeptiDream EV-to-EBITDA Historical Data

The historical data trend for PeptiDream's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PeptiDream EV-to-EBITDA Chart

PeptiDream Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 86.16 71.81 26.09 21.61 13.21

PeptiDream Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.48 9.14 11.72 13.21 11.30

Competitive Comparison of PeptiDream's EV-to-EBITDA

For the Biotechnology subindustry, PeptiDream's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PeptiDream's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PeptiDream's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PeptiDream's EV-to-EBITDA falls into.


;
;

PeptiDream EV-to-EBITDA Calculation

PeptiDream's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1392.842/148.587
=9.37

PeptiDream's current Enterprise Value is $1,392.8 Mil.
PeptiDream's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $148.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PeptiDream  (OTCPK:PPTDF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

PeptiDream's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=13.53/0.716
=18.90

PeptiDream's share price for today is $13.53.
PeptiDream's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.716.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


PeptiDream EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PeptiDream's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


PeptiDream Business Description

Traded in Other Exchanges
Address
1-2-10, Nihonbashi, Chuo-ku, Toyo Building, 6th Floor, Tokyo, JPN, 103-0027
PeptiDream Inc is a biopharmaceutical company, engaged in the research and development of new pharmaceutical candidates. It discovers constrained peptides, small molecules, and peptide-drug conjugate therapeutics using its Peptide Discovery Platform System. The company aspires to be a leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide.